Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

BACKGROUND. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in pati...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Oncologist
Główni autorzy: Kadakia, Kunal C., Snyder, Claire F., Kidwell, Kelley M., Seewald, Nicholas J., Flockhart, David A., Skaar, Todd C., Desta, Zereunesay, Rae, James M., Otte, Julie L., Carpenter, Janet S., Storniolo, Anna M., Hayes, Daniel F., Stearns, Vered, Henry, N. Lynn
Format: Artigo
Język:Inglês
Wydane: AlphaMed Press 2016
Hasła przedmiotowe:
Breast Cancer
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4861358/
https://ncbi.nlm.nih.gov/pubmed/27009936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0349
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy